PT  - JOURNAL ARTICLE
AU  - A. NÉMETH
AU  - E. NADASI
AU  - A BERO
AU  - L. OLASZ
AU  - A. EMBER
AU  - A. KVARDA
AU  - L. BUJDOSO
AU  - I. ARANY
AU  - A. CSEJTEI
AU  - ZS. FALUHELYI
AU  - I. EMBER
TI  - Early Effects of Transplatin on Oncogene Activation <em>In Vivo</em>
DP  - 2004 Nov 01
TA  - Anticancer Research
PG  - 3997--4002
VI  - 24
IP  - 6
4099  - http://ar.iiarjournals.org/content/24/6/3997.short
4100  - http://ar.iiarjournals.org/content/24/6/3997.full
SO  - Anticancer Res2004 Nov 01; 24
AB  - The aim of the study was to investigate the early effect of Transplatin (the stereo-isomer of Cisplatin) on oncogenes in inbred CBA/Ca mice. Cisplatin is commonly used for the treatment of squamous cell carcinomas of the head and neck. Cisplatin has a strong oncogene activation effect compared to the structural analogue Transplatin. Body weight equivalent amounts of a human dose of Transplatin were administered intraperitoneally to 6- to 8-week-old, inbred, female CBA/Ca mice. Twenty-four, 48 and 72 hours after the treatment, RNA was isolated from the target organs and the expressions of c-myc, Haras and p53 genes were examined. Investigation of early changes showed no significant overexpression compared to Cisplatin, which had a significant effect on oncogene expression in the “short-term” in vivo test system. Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved